Immunomic Therapeutics CEO to Present at Precision Medicine World Conference (PMWC): Emerging Therapeutics Showcase
DURHAM, N.C.--(BUSINESS WIRE)--Sep 24, 2018--Tomorrow, Dr. William Hearl, Ph.D., Chief Executive Officer (CEO) of Immunomic Therapeutics, Inc. will present at the Precision Medicine World Conference, Duke Program, in the Emerging Therapeutics Showcase in Durham, North Carolina. Dr. Hearl will discuss the potential capabilities of Immunomic’s UNiversal Intracellular Targeted Expression (UNITE) investigational technology platform as a comprehensive platform for precision immune-oncology and beyond. Immunomic’s nucleic acid vaccines have the potential to utilize the body’s natural biochemistry to develop a broad immune response including antibody production, cytokine release and critical immunological memory. This approach could put UNITE at the crossroads of immunotherapies in a number of illnesses, including cancer, allergy and infectious diseases. Immunomic’s lysosomal targeting technology is currently being employed in a Phase II clinical trial as a cancer immunotherapy.
Who: Dr. Bill Hearl, Ph.D., CEO at Immunomic Therapeutics, Inc.
What: Presentation at Precision Medicine World Conference, Duke Program: Emerging Therapeutics Showcase
When: Tomorrow, Tuesday, September 25 at 1:30 p.m. EDT
Where: Washington Duke Inn and Golf Club, 3001 Cameron Boulevard, Durham, NC 27705
ITI’s investigational UNITE platform, or UNiversal Intracellular Targeted Expression, is thought to work by encoding the Lysosomal Associated Membrane Protein, an endogenous protein in humans. In this way, ITI’s vaccines (DNA or RNA) have the potential to utilize the body’s natural biochemistry to develop a broad immune response including antibody production, cytokine release and critical immunological memory. This approach could put UNITE technology at the crossroads of immunotherapies in a number of illnesses, including cancer, allergy and infectious diseases. UNITE is currently being employed in Phase II clinical trials as a cancer immunotherapy. ITI is also collaborating with academic centers and biotechnology companies to study the use of UNITE in cancer types of high mortality, including cases where there are limited treatment options like glioblastoma and acute myeloid leukemia. ITI believes that these early clinical studies may provide a proof of concept for UNITE therapy in cancer, and if successful, set the stage for future studies, including combinations in these tumor types and others. Preclinical data is currently being developed to explore whether LAMP nucleic acid constructs may amplify and activate the immune response in highly immunogenic tumor types and be used to create immune responses to tumor types that otherwise do not provoke an immune response.
About Immunomic Therapeutics, Inc.
Immunomic Therapeutics, Inc. (ITI) is a privately-held clinical stage biotechnology company pioneering the study of the LAMP-based nucleic acid immunotherapy platforms. These investigational technologies have the potential to alter how we use immunotherapy for cancer, allergies and animal health. ITI has entered into a significant licensing agreement with Astellas Pharma Inc. to explore the use of LAMP-Vax, the precursor to UNITE, an immunotherapy platform, for use in the prevention and treatment of allergic diseases. For information about ITI and UNITE technology, visit www.immunomix.com.
View source version on businesswire.com:https://www.businesswire.com/news/home/20180924005008/en/
CONTACT: Immunomic Therapeutics
Sia Anagnostou, 717-327-1822
KEYWORD: UNITED STATES NORTH AMERICA NORTH CAROLINA
INDUSTRY KEYWORD: HEALTH BIOTECHNOLOGY CLINICAL TRIALS ONCOLOGY RESEARCH SCIENCE
SOURCE: Immunomic Therapeutics
Copyright Business Wire 2018.
PUB: 09/24/2018 06:00 AM/DISC: 09/24/2018 06:01 AM